3-Butanoyl-1,8-dihydroxy-2-methylphenanthrene-9,10-dione | 100843-91-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: 3-Butanoyl-1,8-dihydroxy-2-methylphenanthrene-9,10-dione
• CAS: 100843-91-2
• 化学式: C₁₉H₁₆O₅
• 分子量: 324.3
• InChiKey: YJQYHFMKGAVKDP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  91.7
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5]OXADIAZOLO[3',4':5,6] PYRAZIONO[2,3-B]INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS<br/>[FR] PROCÉDÉS ET COMPOSITIONS D'ANALOGUES SUBSTITUÉS DE 5H-[1,2,5]OXADIAZOLO[3',4':5,6] PYRAZIONO[2,3-B]INDOLE UTILISÉS COMME INHIBITEURS DES INTERACTIONS PROTÉINE-PROTÉINE BÊTA-CATÉNINE/FACTEURS TCF
  申请人：UNIV UTAH RES FOUND

  公开号：WO2016187050A1

  公开（公告）日：2016-11-24

  In one aspect, the invention relates to substituted 5H-[1,2,5]oxadiazolo [3',4':5,6]pyrazino[2,3-b]indole analogues, derivatives thereof, and related compound; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g., various tumors and cancers, associated with a β-catenin/T-cell factor interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在一个方面，该发明涉及替代的5H-[1,2,5]噁二唑[3',4':5,6]吡唑并[2,3-b]吲哚类似物，其衍生物以及相关化合物；制备这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与β-连环蛋白/T细胞因子相互作用功能障碍相关的疾病的方法，例如各种肿瘤和癌症。本摘要旨在作为在特定领域搜索的扫描工具，并不旨在限制本发明。
• Methods and compositions of substituted 5H-[1,2,5] oxadiazolo [3′,4′:5,6] pyrazino[2,3-B] indole analogs as inhibitors of β-catenin/T-cell factor protein-protein interactions
  申请人：University of Utah Research Foundation

  公开号：US10273246B2

  公开（公告）日：2019-04-30

  In one aspect, the invention relates to substituted 5H-[1,2,5]oxadiazolo [3′,4′:5,6]pyrazino[2,3-b]indole analogs, derivatives thereof, and related compound; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and A methods of treating disorders, e.g., various tumors and cancers, associated with a β-catenin/T-cell factor interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在一个方面，本发明涉及取代的5H-[1,2,5]噁二唑并[3′,4′:5,6]吡嗪并[2,3-b]吲哚类似物、其衍生物和相关化合物；制造这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与β-catenin/细胞因子相互作用功能障碍相关的疾病，例如各种肿瘤和癌症的方法。本摘要旨在作为一种扫描工具，用于特定技术领域的检索，并非对本发明的限制。
• Anti-CD70 combination therapy
  申请人：University of Bern

  公开号：US10391168B1

  公开（公告）日：2019-08-27

  Provided are methods and compositions for the treatment of a BCR-ABL1 related disorder (e.g., chronic myelogenous leukemia) using a therapeutic combination of a WNT signaling pathway inhibitor and a BCR-ABL1 tyrosine kinase inhibitor.

  本文提供了使用WNT信号通路抑制剂和BCR-ABL1酪氨酸激酶抑制剂的治疗组合来治疗BCR-ABL1相关疾病（如慢性粒细胞白血病）的方法和组合物。
• Methods for treating diseases related to the wnt pathway
  申请人：Sandia Corporation

  公开号：US10624949B1

  公开（公告）日：2020-04-21

  The present invention relates to methods for treating a disease, in which the disease arises from dysregulation of the Wnt signaling pathway. In some instances, the disease can be treated by administering a Wnt pathway inhibitory compound. In other instances, the method optionally includes conducting a genome-wide screening to determine one or more genes resulting in a reduced disease state and then identifying the gene(s) as being involved in the Wnt signaling pathway.

  本发明涉及治疗疾病的方法，其中疾病是由 Wnt 信号通路失调引起的。在某些情况下，可以通过施用抑制 Wnt 通路的化合物来治疗疾病。在其他情况下，该方法可选地包括进行全基因组筛选，以确定导致疾病状态降低的一个或多个基因，然后确定这些基因参与Wnt信号通路。
• US20140255426A1
  申请人：——

  公开号：US20140255426A1

  公开（公告）日：2014-09-11